The percentage of CD19+CD24highCD38high Bregs in BM CD19+ B cells from AML patients was significantly increased compared with those from healthy participants (7.50% [range: 5.20 to 12.65%] vs 4.80% [range: 2.05 to 6.95%], P = 0.0255) (Fig. 5b). This evidence concerns the gene CD19 and acute myeloid leukemia.